WAS

Across TCGA pan-cancer cohorts, WAS mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of WAS’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where WAS mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types WAS is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where WAS tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in WAS mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+1.011	<.001	11	view →
COAD	All	All	−0.136	<.001	8	view →
LSCC	Male	II,III,IV	−0.321	<.001	6	view →
LUAD	All	II,III,IV	−0.204	<.001	6	view →
PDAC	Female	All	+0.498	<.001	5	view →
HNSC	All	All	+0.256	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

WAS–CCRCC

Open the CCRCC breakdown →